Larvol Delta - Study-of-RiMO301-and-Radiotherapy-With-PD1-Inhibitor-for-the-Treatment-of-HeadNeck-Cancer

RiMO-301 - Coordination Pharma

Opdivo (nivolumab) - Ono Pharma, BMS

Keytruda (pembrolizumab) - Merck (MSD)

http://clinicaltrials.gov/ct2/show/NCT05838729

Dec 18, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next